Conditions: Alzheimer's Disease Cognitive Impairment
Keywords: Mild Alzheimer's disease (AD) patients Memory complaint patients with cognitive impairment (MC) Memory complaint patients cognitively normal (CNE)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 49
Healthy volunteers: no

Brief summary:
The aim of the study is to evaluate the effect of EGb761®, in comparison to placebo, on cerebral glucose metabolism, in three groups of elderly patients: newly diagnosed mild Alzheimer's disease (AD), memory complaint patients with cognitive impairment (MC) and memory complaint patients cognitively normal (CNE). The first phase includes four weeks treatment with EGb761® for all groups, with change in brain glucose metabolism at month 1 using 18 FDG-PET, as primary endpoint which will be followed by an open 17 months follow-up (FU) period with EGb761® treatment in MC and CNE patients.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: EGb761® intervention 2: Placebo
Intervention descriptions: intervention 1: Four weeks for AD patients, 18 months for MC and CNE patients intervention 2: Placebo 1 tablet BID

Protocol document: